Three grants funded by Daiichi Sankyo and AstraZeneca to study HER2 directed and TROP2 directed antibody drug conjugates (ADCs)
NEW YORK, NY (marzo 12, 2024) – The Lung Cancer Research Foundation (LCRF) has announced three research grant awards funded by Daiichi Sankyo and AstraZeneca, totaling $810,000, focused on further developing the understanding of the proposed mechanism of action of antibody drug conjugates (ADCs), exploring biomarkers and blood-based biomarkers for the primary and acquired resistance mechanisms to TROP2- or HER2-directed ADCs, and exploring the use of ADCs in lung cancer types beyond non-small cell lung cancer (NSCLC).
ADCs are designed to specifically target cancer cells and selectively deliver a highly potent payload, which may limit damage to healthy cells. An ADC comprises a monoclonal antibody that recognizes a protein present on the cancer cells, and is bound to a cytotoxic agent, known as the payload.
The use of ADCs is common practice in several cancers, and currently, multiple phase 3 trials of ADCs in NSCLC are underway.
“LCRF is honored to continue its long legacy of identifying and supporting outstanding lung cancer research projects over the years, and we are excited to present these grants made possible by this research collaboration,” said Dr. Antoinette Wozniak, LCRF’s chief scientific officer. “The study of ADCs is an exciting development in lung cancer research with considerable promise for increased positive outcomes for patients.”
2023 LCRF – Daiichi Sankyo – AstraZeneca Research Grant on Antibody Drug Conjugates award recipients include:
Aakash Desai, MD, MPH, University of Alabama at Birmingham Deciphering the ADC code: a proteogenomic quest in lung cancer
Carl Gay, MD, PhD, University of Texas, MD Anderson Cancer Center Pulmonary high-grade neuroendocrine carcinomas as indications for antibody drug conjugates targeting TROP2 and HER2
Nan Sethakorn, MD, PhD, Loyola University of Chicago Leveraging liquid biopsy to identify the optimal clinical niche for TROP2-targeting in NSCLC
To learn more about LCRF and its grants program, visit LCRF.org
# # #
About the Lung Cancer Research Foundation (LCRF) The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 418 research grants, totaling nearly $44 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information, visit LCRF.org.
On marzo 5, recipients of the 2022 LCRF and EGFR Resisters Research Grant on EGFR-Driven Lung Cancer provided an informative update on their research projects.
Ivy Elkins and Jill Feldman from EGFR Resisters hosted speakers Jonathan Ostrem, MD, PhD, University of California, San Francisco; Swarnali Acharyya, PhD, Columbia University Medical Center; and Luke Hoeppner, PhD, University of Minnesota, Twin Cities.
“For 14 years, I have been all around the world serving my country on the U.S. Air Force. I’m a dad. A husband. A brother. I’m a son – all of those things. And currently I am fighting stage 4 lung cancer.”
In 2020, Xavier contracted Covid and was off flying status for longer than expected. A physical revealed a spot on his lung, but it wasn’t a concern until about three months later when it had doubled in size. “That’s when all the red flags started going off,” he said.
Xavier had a biopsy in julio 2022. “The biopsy went from pretty much, ‘let’s get this spot out of here’ to ‘oh no, there’s a lot of cancer.’” All of the 15 lymph nodes biopsied were cancerous. The cancer has since spread to Xavier’s liver, and weeks ago, he was told he had 20 to 30 tumors in his brain.
“When I got this surgery, the surgeon was like, there’s no way you’re this young and your lungs look that bad. You had to go somewhere to get this – the only way I’ve seen things like this is from 80-year-old men who have been working in factories their whole lives and smoking a pack of cigarettes every day. But I think of all the deployments, all the burn pit exposures that I’ve had, all the things that we burned, all the hazards and chemicals.”
In the video clip at left, Xavier talks about why advocating for service members is so important.
Although Xavier has a very supportive command team, he is concerned for his fellow service members. The military covers most health care expenses but focuses more on the short term – getting people back in to service – than long term outcomes.
“My fear is that there are other service members out there who are dealing with the same thing, and just don’t know how to voice it, or just don’t have the avenues, or just don’t have the resources to reach out. And that’s kind of where I take this fight kind of personally, almost because I don’t want any other service member to experience what I have – waiting for scans or being told, ‘oh, it’s not a big deal,’ or just sitting around and waiting, because a lot of it was just speculation. The first doctor that I went to told me my spot was from some red clay that I grew up from Tennessee, and that couldn’t have been further from the truth.”
Xavier spent a lot of time trying to be okay because he had worked hard for his career and appreciated all the opportunities the Air Force had given him. Sharing his story publicly has given him an avenue to support service members in similar situations.
“A lot of my health care is taken care of because I’m still active duty. But the younger airmen, the younger service members don’t know where to find resources. They don’t know who to talk to. They don’t know what to expect.”
The importance of caregivers
Xavier with Chelsea
Xavier’s wife, Chelsea, has been a source of strength for him. “When I’m out of it, she’s the one in the meeting – she’s the one asking the questions. Caregiver support is huge, because having resources means she can verbalize things on my behalf. A lot of veterans don’t have that, or their caregivers don’t know where to start.”
Chelsea notes that a service member’s ability to endure can mask the pain he or she is experiencing. “I think people have a stereotypical cancer patient in their mind, and they can become insensitive or dismissive when someone doesn’t fit the stereotype.”
She noted that important symptoms may have been missed because of those assumptions. “Because Xavier walked in with a smile, they would assume that things were okay, but they didn’t know or ask. You know who got him dressed? Can he be left home alone? They wouldn’t ask those questions.”
“There probably needs to be more conversation around mental toughness, and how sometimes that’s a barrier to receiving the care you need,” she said.
Xavier sees more gaps in health care than there should be. “We should have help everywhere, because cancer is everywhere. People all over the world, having the same problems, having the same symptoms and experiencing the same things.”
“Cancer can be deadly, but that does not mean it’s a death sentence. Every day we get a new day to fight. There’s more than one way to be seen and be heard, and we just have to step out there and be brave – because at the end of the day we’re fighting for our lives. We’ve already signed a blank check, and the blank check is being cashed right now, and we can’t afford to just sit and just let it continue to be cashed over and over again at the expense of our lives. I want to change the narrative. I want to make a positive change and an impact.”
“Being in the military is already hard with everything that we go through with the sacrifices, and the coming and going, and all the things that come with being in the military. We need to do things in our society and our culture, especially in this realm, where we can make it easier for each other. It’s got to start somewhere, and I’m ready to start it.”
Trillionaires Only
When Xavier was recovering from lung cancer surgery, he and his supporters created a clothing brand, Trillionaires Only. His hope is to share his message and his cancer journey with the world and to show that whether you’re facing your toughest battle or chasing your biggest dream, you must always be authentic, resilient, and ambitious.
On feb. 26, the Veterans Administration announced that all veterans exposed to toxins and other hazards while serving in the military will be eligible to enroll directly in VA health care beginning marzo 5, 2024. Those veterans will be eligible to enroll directly in VA health care without first applying for VA benefits.
This expansion of VA health care eliminates the phased-in approach called for by the PACT Act — meaning that millions of veterans are becoming eligible for VA health care up to eight years earlier than written into law.
My lung cancer story began with a mammogram in febrero 2022. I was 42 years old, and it was my second one ever. All was well except for a calcified blood vessel, which they now flag as a potential sign of atherosclerosis. When I went in for my physical, my doctor noted this and, out of an abundance of caution, ordered a calcium score heart scan, and inexpensive CT scan. The scan resulted in me being put on a statin and revealed a 3 cm lung mass. I was so surprised by both of these things that I wasn’t even that worried the first month, certain they must have mixed up the scans! The next month, we got a chest CT with more detail, and it was still there. The radiologist report said “certainly, this may be adomatous.” I started to worry.
I was referred to a pulmonologist, who pulled up my scan and said that it did not look like Covid and most certainly was not supposed to be there. He asked me about risk factors and symptoms, which I had none of, and he had to note second hand smoke from my grandfather, which was barely the case, so that he could justify follow up. He ordered an emergency PET scan and a bronchoscopy. He told me that he didn’t think this mass would have shown up on a regular x-ray. The PET scan showed only the one mass, lighting up a little bit but not too much. It was a huge relief to know that nothing else was lighting up, but he confirmed that it should not be lighting up at all. Unfortunately, the mass was in a very difficult spot near blood vessels and close to my heart in my left lung, and he was not able to reach it for biopsy during the bronchoscopy. I was very disappointed to still not know for sure what was going on, but I understood that this was for my own safety. I was of course searching online for every single word in every report and getting into support groups for advice. This was actually a time that I needed support groups the most – before diagnosis but after the discovery of the mass.
Robotics for diagnosis
Someone in a support group suggested a robotic bronchoscopy, which makes it possible to reach tough-to-get spots. The other medical group in my area came up when I searched, so I made an appointment for a second opinion with a doctor in their group in hopes that I could get referred to the robotic team. Unfortunately, despite my going in person and signing forms weeks in advance, that doctor did not receive any imaging and only had the written reports. He seemed completely unconcerned and said “some people die with masses like these, not of them.” I said, “Are those people 42 years old?”
Weeks later, after I got another follow up CT to check for progression, he called me out of the blue, quite concerned. He had finally received the imaging, and he wanted to make sure he corrected the original impression he had given me. He told me he didn’t want to scare me but that it definitely looked suspicious. I told him I was already scared and had already requested a surgical consult because I was not comfortable with watching and waiting for a lung mass to prove it was cancer by growing. He seemed relieved. The original pulmonologist had also seemed relieved when I requested a surgical consult. I later thought that perhaps the doctors are instructed to follow a certain protocol – a flow chart – even if their intuition is telling them something different sometimes. Because patient preference can be a part of that protocol, my saying I wanted to talk to a surgeon was all it took to unlock that next step. There was no coordinator through this process trying to get a diagnosis. It was just me being persistent. I thought often about patients who are very busy with work or who do not wish to read as much about medical possibilities as I do.
When I visited the surgeon, he walked in the door and told me my whole story from the mammogram so that I did not have to repeat my story to him. I was immediately impressed. He referred me to a doctor about 1-2 hours away with a lot of experience in robotic bronchoscopy if I wanted to confirm diagnosis but also told me he was completely on board with removing the mass regardless because even benign masses can grow and cause issues. We decided to do it so we could be sure before major surgery. Being in a different town and a different medical group was a bit strange and made me more grateful for the care I had received to that point, even though it required my persistence and advocating for myself. However, the doctor himself was very experienced with the robotic bronch and got a successful biopsy. He was able to tell under the microscope in the room what it was and told my husband that it was indeed cancer. I did not know (or didn’t remember due to the drugs), and I remember a nurse asking me how they found the mass. They way she was talking to me told me right away that they had confirmed cancer. That was in agosto 2022. Strangely, this felt like a bit of relief because I finally knew for sure what it was and could confidently go ahead with surgery.
‘Cancer is not usually a great conversation starter’
I am the first person in my family to have cancer other than basal cell skin cancer. It was very surreal and unbelievable – it still is. I realized that I had no idea if I should tell other people or if I wanted to, and I also felt aware that it was such a heavy topic that it sometimes almost seemed unkind to tell someone about it. Cancer is not usually a great conversation starter. I gradually found that the more people I told, the more it helped me accept it as fact, and I felt supported and understood by those who were willing to talk about it with me and let me tell my story.
I had two friends who have had hard fights with breast cancer reach out right away with calls and gifts and cards. My sister – a medical writer with a background in pharmaceutical development – would get into the weeds with me and read the medical papers and research to decide what to do next, and I felt very supported by that. Many people sent cards and brought food while my husband was trying to handle the kids alone (even though he is normally our chef, that’s a lot harder when you are doing everything else!). My husband and I cried together a few times, and being able to just let out that fear mixed with a little bit of relief of dodging a bigger bullet. The No Surprises Act was passed not long before my surgery, and when I called my insurance and found out that I would not pay anything out of pocket for my surgery, I unexpectedly burst into tears.
When we told the kids, we assured them that it was caught early and that I would be okay, and they seemed to take it in stride. The surgeon told me very confidently that I was early stage and that surgery could cure me. While I appreciated his optimism, I also was very skeptical of this point of view. Lung cancer is quite an a-hole, and I still do not feel comfortable with the word “cure.” As much as I appreciated him, I felt more doubtful about follow up. He performed a lower left lobectomy in septiembre 2022. It was a 3cm mass with about 9mm negative margins. Visceral pleural invasion was present, and so I am stage 1B.
I was only in the hospital for about 24 hours. They had me up and walking quickly. Even though it was hard and painful, I knew it was important. They removed the chest tube not even 24 hours after surgery, and I was sent home with only one night in the hospital. There were travel nurses who were just meeting each other, and while they did give me a pillow that people could sign, there was no one to sign it.
I developed a really annoying cough while recovering at home and couldn’t even speak for days because of it. We later learned that they had removed the chest tube too soon, and I had pleural effusion. I had to eventually have it drained in enero at another provider. Recovery was otherwise not too bad – I did use a recliner for sleeping and walked as much as possible. There were nights, however, when I would search online for stories of survivors of lung cancer, and I would repeatedly come up empty. I found many stories of people like me who didn’t catch it in time or had recurrence. I had to tell myself that the people who survived didn’t need the support anymore or have a reason to speak out, so they were living their lives. I decided that for as long as I could, I would stay in support groups and tell this story so that people would be able to find a happy ending when they search at night.
I had a follow up about a month or two after surgery, and they said they would do CT scans every 6 months for follow up but that I otherwise did not qualify for any adjuvant therapy. I asked for an oncologist referral, and she shared the biomarker results with me. However, she misinterpreted the results and thought that the EGFR genetic mutation was only eligible for targeted therapy if it was L858R. I was exon 19 del. She also seemed to think that the targeted therapies listed on the report were in order of efficacy when they were actually just in alphabetical order. My sister helped me review the data and confirmed that I should get a second opinion and try to find an EGFR specialist. I am very grateful for the care I now receive at the Duke Cancer Center.
I was placed on Tagrisso (osimertinib) as targeted therapy to help hold back any potential microscopic cells still roaming around. I receive CT chest and abdomen scans with blood work every 3 months and MRI every 6 months. I believe the trial protocol for Tagrisso in people of my stage is 3 years, so I don’t know what will happen in 2025. I would feel more comfortable if I could stay on it 5 years.
When I was first diagnosed, I wish I had known how important and necessary second opinions are. You are not a hypochondriac if you are learning about your disease online – you are a warrior becoming an expert on the specific markers and aspects of what’s going on in your body, and that level of expertise is a strong asset when consulting with doctors. I wish I had known about the funding deficits despite being the most deadly cancer so that I could have advocated for lung cancer awareness and funding more when I was spending more time in medical facilities.
In noviembre, for Lung Cancer Awareness Month, I decided to raise funds for research by having a Cancerversary party. People with lung cancer deserve more happy endings, and research will get us there.
Organizations team up to increase lung cancer screening through a student-led, community-based initiative
NEW YORK, NY (febrero 20, 2024) – The Lung Cancer Research Foundation (LCRF) and the American Lung Cancer Screening Initiative (ALCSI) are partnering to improve early detection of lung cancer through a campaign and associated research study titled “ALCSI-LCRF Plus One Campaign,” sponsored by AstraZeneca.
Lung cancer is the deadliest cancer in the United States, and in 2024, an estimated 125,070 Americans will die from lung cancer. Early detection of lung cancer through low-dose computed tomography (LDCT) screening is the most promising way to improve the survival of patients diagnosed with lung cancer. However, fewer than 5% of Americans eligible for screening are currently getting screened. A major barrier to improving the uptake of lung cancer screening in the United States is the low public awareness of lung cancer screening and the difficulty of reaching those individuals who currently qualify for lung cancer screening. Large-scale awareness campaigns that can effectively reach individuals who qualify for lung cancer screening and encourage them to get screened are urgently needed.
With the “Plus One” campaign, ALCSI will leverage its more than 50 chapters at universities across the United States to engage students in a grassroots effort to increase lung cancer screening awareness. The crux of the “Plus One” campaign is that the messaging will shift from directly asking people “Are you eligible for lung cancer screening?” to asking, instead, “Do you have a friend or loved one who is eligible for lung cancer screening?” (the “Plus One Message”). Through word-of-mouth and direct one-on-one conversations about lung cancer screening, the “Plus One” Campaign will apply a highly novel strategy to increase awareness of and use of lung cancer screening in the United States. The “Plus One” campaign will be implemented at up to 50 geographically diverse sites across the United States within the next three years.
As part of the execution of the “Plus One” campaign, ALCSI will develop the Lung Cancer Screening Referral Network (Referral Network), tracking the total number of people reached by the “Plus One” campaign, both to measure the effectiveness of the campaign and to further engage people in ALCSI’s activities. Additionally, at select sites, ALCSI will assess the number of people who undergo lung cancer screening before versus after the implementation of the Plus One Campaign to measure the impact of the campaign on increasing screening rates.
Leveraging its relationships with lung cancer community groups, research institutions and industry partners, along with its wide array of educational resources, LCRF will partner with ALCSI on funding support, project administration and reporting, program and education support, and campaign promotion and marketing.
“We are thrilled to be working with ALCSI on this very promising project,” says Aubrey Rhodes, Executive Director of LCRF. “Improving screening rates for lung cancer could save thousands of lives. Engaging students, who are passionate about improving screening rates by educating their communities on screening criteria, will certainly make a difference. We look forward to the potential impact this study will have on patient outcomes.”
“We believe that students have a unique opportunity to engage family members, friends, and colleagues in conversations about screening and early lung cancer detection. These conversations are a simple yet powerful strategy to motivate more high-risk individuals to get screened,” says Alexandra Potter, President of ALCSI. “We are grateful for the opportunity to partner with LCRF on the “Plus One” campaign and look forward to working together to increase awareness of lung cancer screening, improve screening rates, and ultimately, save lives.”
About the Lung Cancer Research Foundation (LCRF) The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 416 research grants, totaling nearly $43 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information about the LCRF grant program and funding opportunities, visit LCRF.org/research.
About the American Lung Cancer Screening Initiative (ALCSI) The American Lung Cancer Screening Initiative (ALCSI) is a 501(c)3 non-profit working to increase awareness of lung cancer screening and help individuals at high risk for lung cancer get screened. The work of the American Lung Cancer Screening Initiative focuses on teaching communities and healthcare providers about the importance of the early detection of lung cancer through screening and working with leaders at the local, state, and national levels to increase awareness of and access to lung cancer screening. To learn more about the American Lung Cancer Screening Initiative and support the work they are doing, visit www.alcsi.org or follow them on Twitter @AmLungCSI, Facebook @americanlungcancerscreeninginitiative, or Instagram @amlungcsi. If you’re interested in working with the American Lung Cancer Screening Initiative to increase awareness of lung cancer and lung cancer screening in your community, email info@alcsi.org.
Contact:
LUNG CANCER RESEARCH FOUNDATION Sheila Sullivan Senior Director, Marketing & Communications ssullivan@lcrf.org
AMERICAN LUNG CANCER SCREENING INITIATIVE Alexandra Potter President info@alcsi.org
The good news Different aspects of lung cancer risk are still poorly understood. This is particularly true of the hereditary risk of developing lung cancer. The presence of the epidermal growth factor receptor (EGFR) mutation T790 in germline cells (cells that can pass on genetic information) can be associated with a hereditary form of lung cancer.
Why it’s important The INHERIT trial studied individuals and their relatives with and without lung cancer evaluating for the EGFR T790 mutation in germline cells (Journal of Clinical Oncology, Volume 41, pages 5274-5284, 2023). They found that 55% of the participants who had this germline mutation were affected by lung cancer usually by age 60. Most of the lung cancers were EGFR mutation positive in somatic (non-inherited) cancer cells. These patients responded well to Osimertinib. The risk of developing lung cancer if a germline mutation was present was variable, which means that having the T790 mutation did not necessarily result in the development of lung cancer. It was also found that patients who did not have lung cancer frequently had lung nodules. These abnormalities would have to be followed for potential development of lung cancer.
What it means for patients This is one of the first studies describing a pattern of inheritance in lung cancer. This may have future implications for individuals who carry this genetic abnormality regarding screening for early detection of lung cancer. This will be especially important for patients who are never smokers.
What to watch for This is just the beginning with respect to understanding the hereditary risk for developing lung cancer. In the future look for similar studies that will help researchers define individuals at risk for lung cancer.
Dann Wonser passed away on junio 30, 2024, 18 years after his diagnosis with lung cancer.
enero 2024
When Dann Wonser was 49 years old – in 2006 – he had an X-ray to determine if he had broken ribs. That’s how he found out he had stage 4 lung cancer. Biomarker testing showed the EGFR and T790M mutations. During the past 18 years, Dann has had:
An upper left lobectomy
Chemo three separate times
Radiation three separate times (hips once, spine twice)
Three targeted therapies
Immunotherapy
One angiogenesis inhibitor
Three clinical trials
Dann with his wife, Gen
Dann credits his wife, Genevieve, and the support of his family and friends with keeping him steady during his treatment – and “beyond that, looking for the realistic positives in any situation, and having realistic expectations,” he said. “No treatment will last forever. So far, there have always been more options, whether clinical trials or standard treatments. I just need to stay healthy enough to get to the next treatment if this one stops working.”
“When I’m going through a hard time, even a simple one-line email or text can provide a big lift. One friend makes me soup or bread, even when I’m doing well and don’t have any special needs. Another friend sent me daily text messages of support for over a year, and then sent cards to me every couple of weeks for about that long, again not always when I was in great need. Just knowing that people are there for me and that they care makes all of the difficult times much easier to cope with.”
Dann’s history with lung cancer has given him valuable insight, and his blog (DannWonser.com) is an avenue for sharing his experiences and advice for others on this journey. He also has written a book, Second Wind: Thriving With Cancer.
Here’s what he would tell those who are newly diagnosed:
Have hope. Cancer treatment is exploding right now. It’s just incredible how fast things are changing – for the better.
Finding out is the hardest part. The first days, weeks, or even months are overwhelming for everyone. You will get past this – we all do. Just remember that what you are going through right now is harder than everything else you will go through. Everything else combined. The reason? You don’t have any tools to deal with it yet. That will change.
Let people in. My life is much richer and more full of love now than it ever was. That only came from sharing my trials and vulnerabilities. I have no doubt that I am alive today because of the love of, and for, family and friends. Rarely people vanished because they couldn’t cope with my cancer, and I can understand this. Much more often, people surprised me with their outpouring of caring and love. Take the risk. Still, it’s easier if you…
Plan how you are going to share your diagnosis with others. I found that by emailing people I cared about before talking with them about it, it saved me from endlessly re-living those first moments after being diagnosed, after the cancer had grown, or spread, or didn’t shrink when I had high hopes. This gave friends and family time to compose themselves before they talked with me, and because of that, the conversations went much better. This way I could also set the tone that I hoped that they would reflect back to me. It works.
Throw the statistics out the window. If you’ve been diagnosed for longer than 12 hours, you have probably already done an internet search and tried to calculate your survival odds and/or your new life expectancy. Finding statistics that match your specific situation is nearly impossible. For example, the average age of diagnosis for lung cancer is 71. I was 49. Do you think treatment outcomes will be the same? General health, the genetic profile of your cancer, environmental factors, location/size/number of tumors etc. – there are too many variables to make the stats make any sense for an individual. Beyond that, your attitude and actions make a difference.
More importantly, whatever statistics you find are probably hopelessly out of date. New treatments are coming online too fast for the statistics to keep up.
A diagnosis is not a prognosis. I attended a conference last year with 150 lung cancer survivors. Most of us attending have, or had, Stage IV lung cancer, and a dozen have been alive for at least five years. If that’s not enough, I am your living example. I was first diagnosed in 2006. One woman I know has had five different cancers, and is still alive 25 years later. The same diagnosis yields different results for different people.
Do your homework. Your survival chances are directly related to the quality of the treatment providers you work with. Is your oncologist a specialist in your specific type of cancer? As a general rule, the more people that your doctor and your treatment center have treated that have the same type of cancer as yours, the higher their success rate. Experience makes a difference. Who are the recognized experts in your type of cancer that are within a radius that you are willing to travel?
Get molecular testing. The most promising breakthroughs in cancer treatment are at the molecular level. This includes both targeted genetic treatments and immunotherapy. If your oncologist doesn’t think you need it, consider the possibility that your oncologist is out of step with the latest research. You may want a second opinion.
Re-think clinical trials. “Clinical trials” used to be considered the last gasp desperation approach to treatment. The reality is that, for lung cancer and many other types of cancer, this is where you will find the most promising, cutting-edge medicine, with the best results, and with the least side effects.
Exercise, sleep, and diet all make a difference. They impact your mood and your ability to cope. More importantly, you will recover from medication, radiation, and surgery better and faster if you are in the best shape you can be. Take care of yourself. Exercise, sleep, and diet. In that order. One man’s opinion.
Attitude matters. Treasure the moment. Live in gratitude for what you have right now. Choose hope. These things not only improve your quality of life, they also improve your chances of living a longer life.
Love yourself. Treat yourself like you matter. Because you do. This may be your last chance to act like it.
Choose your own path. I’ve laid out the way I see it. You may see it differently. Find your own vision of the future, and own it.
Radon is a naturally occurring radioactive gas, produced when uranium breaks down. This gas is released through rocks, soil, and water, and can build up in enclosed spaces through cracks in a building’s foundation or other openings. Because it’s invisible and odorless, radon exposure doesn’t cause immediate symptoms.
However, radon is the second-leading cause of lung cancer, resulting in more than 21,000 deaths every year in the U.S. It is the leading cause of lung cancer for non-smokers.
The highest concentrations of radon develop in spaces below ground level without much ventilation: basements, crawlspaces, foundations, sump pumps, and construction joints. While pockets of radon can be found across the country, some states have higher levels than others. Check your state’s radon levels here.
If you live in an older home, or in a state with higher radon levels, be sure to test your home for the presence of radon. Safewise.com recommends these six detectors.
How much radon is too much? Radon detectors measure levels in picocuries per liter (pCi/L) to indicate average, year-round radon levels. If your home measures between 2-4 pCi/L, consider taking steps to reduce radon levels. Higher than 4? Confirm the results, then take immediate action. The EPA offers more information here.
The good news The US Food and Drug Administration (FDA) approved repotrectinib (AugtyroTM) for the treatment of patients with advanced ROS-1 fusion non-small cell lung cancer (NSCLC) in noviembre of 2023. The approval was based on findings from the TRIDENT-1 trial, published on enero 11, 2024 in The New England Journal of Medicine. The first author of the paper is former LCRF grantee, Alexander Drilon, MD, from Memorial Sloan Kettering Cancer Center (MSKCC.)
Why it’s important Repotrectinib was evaluated in the TRIDENT-1 trial. 79% of patients who had not received prior treatment for their cancer responded to the drug. The control of the cancer lasted close to 3 years. Repotrectinib was especially effective in patients whose cancer spread to the brain.
What it means for patients Patients with ROS-1 positive lung cancer have a new, effective treatment option. Since ROS-1 fusions are rare, it is very important that patients with newly diagnosed advanced NSCLC have molecular testing done on their cancer to provide appropriate treatment. If a patient has the ROS-1 fusion, they should discuss treatment options along with the associated risks and benefits with their Oncologists.
What to watch for Repotrectinib is a new treatment option but unfortunately it is not a cure for these NSCLC patients. In the future we will see more studies evaluating why cancers develop resistance and how we can overcome it. There will also be further drug development to improve on currently available treatments.
Lung cancer research grant mechanisms open for submission
NEW YORK, NY (enero 11, 2024) – Today, the Lung Cancer Research Foundation (LCRF) announced that its 2024 funding mechanisms are now open for submission.
LCRF’s four core funding mechanisms are aimed at furthering its commitment to funding investigators who are dedicated to finding solutions to the most pressing issues in lung cancer, including: early detection, gaining new insights into lung cancer biology, understanding mechanisms of and finding new approaches to overcome and/or prevent drug resistance, and uncovering novel and innovative approaches to the treatment of lung cancer. The organization also aims to address inequities in the careers of investigators from underrepresented groups in cancer research.
“It is always exciting to announce LCRF’s Requests for Proposals,” said Katerina Politi, PhD, Chair of LCRF’s Scientific Advisory Board, Cancer Biologist and Professor at Yale’s School of Medicine. “Each year, LCRF funds innovative new ideas to understand treatment resistance, tackle disparities, increase the diversity of the lung cancer research workforce and support science that seeks solutions to lung cancer’s many complexities. The LCRF Scientific Advisory Board looks forward to reviewing the many novel applications we will receive through this process.”
“The responses LCRF receives each year from these talented investigators is remarkable,” said Colleen Conner Ziegler, lung cancer survivor and LCRF board chair. “Each new grant cycle brings more hope for innovative solutions that will impact patients in a meaningful way. The only thing more exciting than this is awarding the grants!”
The LCRF Leading Edge Research Grant, previously known as the LCRF Pilot Grant, seeks to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. This funding mechanism seeks novel ideas, approaches, methods, and techniques that promise to have a profound impact on lung cancer patients and their treatment teams.
LCRF’s Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer is focused on identifying, characterizing, and developing approaches that will detect lung cancer at the earliest stages. Given the significance and need for early detection of lung cancer and advancements in screening, this funding mechanism aims to support research projects that facilitate or advance the understanding and characterization of pre-neoplasia or approaches for early detection, in non-small cell and small cell lung cancer.
The LCRF Research Grant on Understanding Resistance in Lung Cancer will focus on understanding resistance and support research projects with an emphasis on characterizing, identifying, treating, overcoming, or preventing resistance to therapies in lung tumor cells, tissues, mouse models, or patients. This mechanism will address important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship.
LCRF’s Minority Career Development Award (CDA) for Lung Cancer is a two-year career development award intended to support early-stage scientists from underrepresented groups working in lung cancer in diverse areas of research including basic, clinical, translational, disparities, and social determinants of health research. The objective of this award is to increase the number of highly skilled and trained researchers from groups that are historically underrepresented in academia, medicine, and leadership in lung cancer research. This program aims to increase representation of investigators from these groups in lung cancer research.
Each of these funding mechanisms will award $150,000 over two years for selected projects, and all mechanisms will be reviewed through a two-step process: Letters of Intent will be accepted until midnight on marzo 4, 2024; if selected, investigators will then be chosen to submit full proposals following a rigorous scientific review. More details about each of the Requests for Proposal, along with eligibility, requirements, and deadlines can be found at LCRF.org/funding.
# # #
About the Lung Cancer Research Foundation (LCRF)
The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 416 research grants, totaling nearly $43 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information about the LCRF grant program and funding opportunities, visit LCRF.org/research.
Contact: LUNG CANCER RESEARCH FOUNDATION Sheila Sullivan Sr. Director, Marketing & Communications ssullivan@lcrf.org